Searchable abstracts of presentations at key conferences in obesity

ob0001a01 | (1) | UKCO2019

Redesigning a Tier 3 Weight Management Service through the use of a mobile application

King Rhodri , Harateh Damian , Fang Wentian , Bull Amy , Murray-Gourlay Alice , Little Marie , Andrews Robert , Douek Isy

Background: The weight management service at Musgrove Park Hospital (MPH) receives around 30 new referrals a month which are currently triaged to be seen jointly by a physician and dietitian at the same visit, with a referral to treatment time (RTT) of 28–32 weeks. The number of patients the service can see each month is limited by incompatible work patterns and lack of clinic space. We are receiving increasing numbers of referrals for complications of bariatric surgery s...

ob0004p3 | Presented Posters | OU2024

Proposed prioritisation framework for the introduction of new medical therapies for weight management in the NHS

Boyle Luke D , Albor Christo , Anyiam Oluwaseun , Sen Gupta Piya , Coelho Claudia , Crane James , K Dimitriadis Georgios , Andrews Robert , Hughes David , Idris Iskandar , Tan Tricia , M McGowan Barbara , McCullough Kath

Until recently, only two medications were licenced and approved by the National Institute of Health and Care Excellence (NICE) for weight loss, orlistat and liraglutide. Semaglutide 2.4mg was launched in September 2023. Both liraglutide and semaglutide belong to a class of drugs called GLP-1 analogues, also used in the treatment of Type 2 diabetes. Successful weight loss outcomes for GLP-1 analogues has led to increased global demand and shortages. In June 2023, a National Pat...